

## MIT Open Access Articles

*Genetic and molecular analyses reveal an evolutionary trajectory for glycan synthesis in a bacterial protein glycosylation system*

The MIT Faculty has made this article openly available. **Please share** how this access benefits you. Your story matters.

**Citation:** Borud, B. et al. "Genetic and Molecular Analyses Reveal an Evolutionary Trajectory for Glycan Synthesis in a Bacterial Protein Glycosylation System." Proceedings of the National Academy of Sciences 108.23 (2011): 9643-9648. Web. 8 Feb. 2012.

**As Published:** <http://dx.doi.org/10.1073/pnas.1103321108>

**Publisher:** Proceedings of the National Academy of Sciences (PNAS)

**Persistent URL:** <http://hdl.handle.net/1721.1/69055>

**Version:** Final published version: final published article, as it appeared in a journal, conference proceedings, or other formally published context

**Terms of Use:** Article is made available in accordance with the publisher's policy and may be subject to US copyright law. Please refer to the publisher's site for terms of use.



# Genetic and molecular analyses reveal an evolutionary trajectory for glycan synthesis in a bacterial protein glycosylation system

Bente Børud<sup>a,1</sup>, Raimonda Viburiene<sup>a</sup>, Meredith D. Hartley<sup>b</sup>, Berit Smestad Paulsen<sup>c</sup>, Wolfgang Egge-Jacobsen<sup>a,d</sup>, Barbara Imperiali<sup>b</sup>, and Michael Koomey<sup>a</sup>

<sup>a</sup>Center for Molecular Biology and Neuroscience and Department of Molecular Biosciences, University of Oslo, 0316 Oslo, Norway; <sup>b</sup>Departments of Chemistry and Biology, Massachusetts Institute of Technology, Cambridge, MA 02139; <sup>c</sup>Department of Pharmaceutical Chemistry, School of Pharmacy, University of Oslo, 0316 Oslo, Norway; <sup>d</sup>Glyconor Mass Spectrometry and Proteomics Unit, University of Oslo, 0316 Oslo, Norway

Edited\* by John J. Mekalanos, Harvard Medical School, Boston, MA, and approved April 28, 2011 (received for review March 3, 2011)

Although protein glycosylation systems are becoming widely recognized in bacteria, little is known about the mechanisms and evolutionary forces shaping glycan composition. Species within the genus *Neisseria* display remarkable glycoform variability associated with their *O*-linked protein glycosylation (*pgl*) systems and provide a well developed model system to study these phenomena. By examining the potential influence of two ORFs linked to the core *pgl* gene locus, we discovered that one of these, previously designated as *pglH*, encodes a glycosyltransferase that generates unique disaccharide products by using polyprenyl diphosphate-linked monosaccharide substrates. By defining the function of PglH in the glycosylation pathway, we identified a metabolic conflict related to competition for a shared substrate between the opposing glycosyltransferases PglA and PglH. Accordingly, we propose that the presence of a stereotypic, conserved deletion mutation inactivating *pglH* in strains of *Neisseria gonorrhoeae*, *Neisseria meningitidis*, and related commensals, reflects a resolution of this conflict with the consequence of reduced glycan diversity. This model of genetic détente is supported by the characterization of *pglH* "missense" alleles encoding proteins devoid of activity or reduced in activity such that they cannot exert their effect in the presence of PglA. Thus, glucose-containing glycans appear to be a trait undergoing regression at the genus level. Together, these findings document a role for intrinsic genetic interactions in shaping glycan evolution in protein glycosylation systems.

epistasis | oligosaccharide biosynthesis | type IV pili

The surfaces of microbial species are dominated by diverse arrays of glycoconjugates that vary in structure and function. Despite their predominance and importance, there remain significant gaps in understanding the origins of polysaccharide diversity at the genetic level and what forces drive glycan diversification. Protein glycosylation systems based on both *N*- and *O*-linked modifications occur in many bacterial species, and among the substrates, surface localized proteins are well represented (1). The broad distribution of these systems strongly suggests that they are advantageous and affect fitness. Detecting selection at the genetic level in these systems is complicated because complex carbohydrates are not primary gene products and because, in many cases, the specific functions of the biosynthetic components and the glycans themselves are incompletely defined. Some systems display robust inter- and intrastain glycan variability, suggesting that glycoform diversification is adaptive. For example, flagellar protein glycosylation systems in *Campylobacter jejuni* and *Clostridium* species display remarkable plasticity in glycoform expression (2–4). However, precise correlations between glycosylation gene content and glycoform phenotypes have been difficult to establish. Similarly, attempts at reconciling the glycosylation gene repertoire with particular populations and ecotypes are problematic. As such, the long-term evolutionary trends and dynamics of protein glycosylation systems remain poorly understood.

The broad-spectrum *O*-linked protein glycosylation (*pgl*) system expressed by species within the genus *Neisseria* represents a unique

model system in which to study bacterial glycoconjugate biology and evolution. Three highly related neisserial species of importance to human health and disease are *Neisseria gonorrhoeae* (the agent of gonorrhea), *Neisseria meningitidis* (an agent of epidemic meningitis), and *Neisseria lactamica* (a commensal colonizing the oropharynx of young children). The genetics of glycan biosynthesis, modification, and transfer to protein have begun to be well characterized in these species (5, 6). Interestingly, some members of these species are capable of undergoing glycan variation as a result of phase-variable, slipped-strand mispairing events within the *pglA* and *pglE* genes (7). These genes are not part of the *pgl* core locus, the products of which function in the synthesis of undecaprenyl diphosphate (UndPP) monosaccharides (PglB, PglC, and PglD) and translocation into the periplasm (PglF) (Fig. 1A). PglA is a galactosyltransferase that acts on the UndPP-monosaccharide, whereas PglE is a galactosyltransferase that extends the PglA-generated UndPP-linked disaccharide to a trisaccharide (Fig. 1A) (8). Both the di- and trisaccharide forms can be further modified via *O*-acetylation mediated by PglI, the gene for which is also capable of undergoing phase variation (8). The *pglB* gene encodes a bifunctional protein with an acetyltransferase domain and a phospho-glycosyltransferase domain responsible for synthesis of 2,4-diacetamido-2,4,6-trideoxyhexose (DATDH). In addition, nearly one half of *N. meningitidis* isolates are reported to have a variant allele of *pglB*, designated *pglB2*, with an ATP grasp domain and a phospho-glycosyltransferase domain responsible for synthesis of glyceramido-acetamido trideoxyhexose (GATDH) rather than DATDH at the reducing end of the glycan (7, 9, 10). Recent studies have demonstrated that the DATDH moiety corresponds to N,N'-diacetylbaucillosamine (diNAcBac) (11). UndPP-linked GATDH precursors generated by PglB2 can be further elaborated by PglA, PglE, and PglI, resulting in at least nine unique protein-associated glycans that can be generated from the neisserial *pgl* pan genome (6). Alleles of *pglB2* appear to have been imported into a *pglB* background from an as yet unidentified source outside of the genus *Neisseria* (9). Given that each neisserial protein-associated glycan displays unique immunogenic and antigenic properties, these data strongly suggest that neisserial *pgl* systems are subject to selective pressures similar to those exerted on other bacterial surface glycoconjugates and adapt to such pressures by mechanisms analogous to those seen in these other systems (12, 13).

In addition to the distinctive reorganization involving *pglB/B2*, a second form of gross polymorphism at *pgl* locus involves the variable presence of two ORFs linked at the *pgl* locus consisting of the *pglF*, *pglB*, *pglC*, and *pglD* genes (Fig. 1B) (7, 10). These ORFs


Author contributions: B.B., R.V., M.D.H., W.E.-J., B.I., and M.K. designed research; B.B., R.V., M.D.H., B.S.P., and W.E.-J. performed research; B.B., R.V., M.D.H., B.S.P., W.E.-J., B.I., and M.K. analyzed data; and B.B., R.V., M.D.H., B.I., and M.K. wrote the paper.

The authors declare no conflict of interest.

\*This Direct Submission article had a prearranged editor.

<sup>1</sup>To whom correspondence should be addressed. E-mail: bente.borud@imbv.uio.no.

This article contains supporting information online at [www.pnas.org/lookup/suppl/doi:10.1073/pnas.1103321108/-DCSupplemental](http://www.pnas.org/lookup/suppl/doi:10.1073/pnas.1103321108/-DCSupplemental).



**Fig. 1.** Glycosylation pathway and core *pgl* locus in *Neisseria*. (A) Current model of the broad spectrum *O*-linked glycosylation systems in *Neisseria*. (B) Gross polymorphisms in the neisserial core *pgl* locus associated with ORFs 2 and 3. Shown are the two states documented in strains of *Neisseria* (7, 10) and in a survey of currently available genome sequences (Table S1): the top configuration represents the ancestral form and the bottom corresponds to the deleted form. The stereotypic deletion retains the first 40 bp of ORF2 and the last 100 bp of ORF3. A 30-bp sequence of unknown origin that spans the ORF2 and 3 sequences is shown in black. Ancestral and deleted forms are found in combination with both *pglB* and *pglB2* allele variants.

are arrayed in tandem between *pglF* and *pglB/pglB2* (in the same orientation as these flanking genes) and are annotated as glycosyltransferases of the CAZy family 4. Each ORF also encompasses monotonous runs of cytosines, suggesting that, if expressed, they might be subject to phase variation. Gonococcal, meningococcal, and commensal strains lacking intact alleles of ORFs 2 and 3 still bear conserved remnants of the 5' end of ORF2 and 3' end of ORF3. This observation indicates that the intact state is ancestral and that a deletion event likely occurred once and then radiated through the metapopulations (Fig. 1B). Intact ORFs were reported in 67% of strains in a predominantly meningococcal strain collection (7), whereas available neisserial genome sequences show their presence in 81% of gonococcal strains, 65% of meningococcal strains, and 94% of commensal strains (Table S1). To date, however, no connections have been established between either ORF2 or ORF3 genotype and glycosylation phenotype (10).

Herein, we examine the potential contribution of ORF3 to protein glycosylation by using a systematic approach with genetically defined recombinant backgrounds, MS analyses, biochemical characterization, and glycan serotyping. Our findings unequivocally demonstrate that PglH (from ORF3) acts as a glucosyltransferase, which uses both UndPP-linked diNacBac and GATDH. These findings thus connect major changes in *pgl* gene content to alterations in glycan repertoire and provide the infrastructure for assessing glycan evolution in this model system.

## Results

**A Previously Uncharacterized Glycosyltransferase Is Associated with Altered Disaccharide Glycan Composition.** To address the potential contributions of ORFs 2 and 3 on neisserial *O*-linked protein glycosylation, loci encompassing them were introduced from diverse neisserial strains into *N. gonorrhoeae* strain N400 in which the *pgl* gene function and associated glycan structures have been defined (8). As ORFs 2 and 3 map between *pglF* and *pglB*, we used a procedure designed to exchange alleles of *pglB/pglB2* by using a counter-selectable marker that allows gene replacement without the presence of selectable markers in the resulting recombinants (6). Specifically, we replaced the N400 locus (carrying the deleted form of ORFs 2 and 3) with those derived from the *N. gonorrhoeae* strain FA1090, *N. meningitidis* strains FAM18 and Z2491, and *N. lactamica* strain ST-640 (Fig. S1). These strains were chosen because they all possess in-frame variants of ORF3. Whereas FAM18 bears the *pglB2* allele predicted to result in GATDH expression, the other strains carry the *pglB* allele. To assess the


impact of the different *pgl* loci on protein glycosylation patterns, mature pilin (PilE) protein was purified from the surface of the recombinant strains. In the *N. gonorrhoeae* background strain N400, the PilE protein subunit is glycosylated with a single disaccharide at serine 63 (14). The intact PilE protein was examined from recombinant strains by using a top-down electrospray ionization (ESI)-MS approach. For recombinants carrying the *pgl*<sub>FA1090</sub>, *pgl*<sub>ST-640</sub>, and *pgl*<sub>Z2491</sub> loci, the reconstructed molecular mass profiles of the corresponding spectra revealed a distribution of species identical to that seen for the parental background. These species corresponded to PilE modified with either the 432-Da glycan moiety [diNacBac-O-acetylated hexose (diNacBac-AcHex)] or a 390-Da glycan moiety [diNacBac-hexose (diNacBac-Hex)] and carrying one or two phosphoethanolamine (PE) moieties (Fig. 2A and Table 1). In the case of the strain carrying the *pgl*<sub>FAM18</sub> locus with a *pglB2* allele, the predominant species corresponded to PilE with either a 436-Da glycan moiety [GATDH-hexose (GATDH-Hex)] or a 478-Da glycan moiety [GATDH-O-acetylated hexose (GATDH-AcHex)] and carrying one or two PE moieties (Fig. 2E). These signals were indistinguishable from those found previously for a recombinant with the meningococcal *pgl*<sub>8013</sub> locus that carries a *pglB2* allele and the deleted conformation of ORFs 2 and 3 (6).

Next, we examined the effects of a *pglA* null mutation (that precludes the addition of galactose to UndPP-linked diNacBac and GATDH sugars) and an ORF3 disrupting mutation. Surprisingly, inactivating *pglA* or ORF3 independently in the N400 *pgl*<sub>ST-640</sub>, N400 *pgl*<sub>Z2491</sub>, and N400 *pgl*<sub>FAM18</sub> backgrounds failed to dramatically alter the MS-based glycoform profiles (Fig. 2B, C, F, and G and Table 1). Specifically, MS analyses demonstrated that N400 *pgl*<sub>ST-640</sub> *pglA* and N400 *pgl*<sub>Z2491</sub> *pglA* continued to generate the diNacBac-AcHex disaccharide whereas N400 *pgl*<sub>FAM18</sub> *pglA* afforded a mixture of GATDH-AcHex disaccharides and GATDH monosaccharide. The latter strain also showed an alteration in microheterogeneity attributable to reduced *O*-acetylation (Fig. 2F). As ORF2 was in an out-of-frame configuration in these three backgrounds, ORF3 was implicated as encoding a glycosyltransferase equivalent to that of PglA (i.e., addition of a hexose moiety to UndPP-linked diNacBac/GATDH sugars). In contrast, mutating *pglA* in the N400 *pgl*<sub>FA1090</sub> background resulted in detection of only diNacBac monosaccharide glycoform (Table 1).

To examine the influence of ORF3 in more detail, an *orf3* null mutation was introduced into the *pglA* recombinant strains. This resulted in strains expressing only the monosaccharide diNacBac and GATDH glycoforms, confirming that ORF3 was responsible for the disaccharide observed in the absence of PglA (Fig. 2D and H and Table 1). Based on these data (summarized in Fig. S2A) and subsequent findings, we designated ORF3 as *pglH*.

We also used monoclonal antibodies recognizing specific epitopes associated with the diNacBac monosaccharide and PglA-dependent diNacBac-Gal forms of protein-associated glycans (6) to assess the impact of PglH on glycan antigenicity in the diNacBac-expressing recombinants. Immunoblotting demonstrated that glycoproteins from all backgrounds with active PglA reacted with npg2 (recognizing diNacBac-Gal), whereas those with PglH alone did not (Fig. S2B). Thus, the disaccharide glycoform associated with PglH activity is an antigenically distinct disaccharide glycan form. In addition, the presence of active PglH in the absence of PglA correlated with the failure to react with the npg1 mAb (recognizing diNacBac monosaccharide) (Fig. S2B). This effect was specific, as npg1 mAb reactivity was restored by introduction of a *pglH* null mutation into the *pglA* backgrounds. These associations were not observed in the strain with the *pgl*<sub>FA1090</sub> locus, consistent with the other data that it carries a defective *pglH* allele.

**PglH Is a Glycosyltransferase Synthesizing an UndPP-Disaccharide.** To determine the glycosyltransferase specificity of PglH, the allele from *N. meningitidis* strain Z2491 was expressed and purified as a maltose binding protein (MBP) fusion. Purified MBP-PglH was incubated with UndPP-diNacBac and radiolabeled versions of five different NDP-sugars: UDP-Glc, UDP-Gal, UDP-GlcNAc, UDP-GalNAc, and GDP-Man. All five of these activated sugars are found endogenously in neisserial species and could serve as the native sub-



**Fig. 2.** ORF3/*pgIH* is associated with altered disaccharide glycan composition. ESI MS analysis of intact PiiE with pili from either the N400 *pgI*<sub>ST-640</sub> or N400 *pgI*<sub>FAM18</sub> strains with different *pgI* backgrounds were carried out to characterize the glycan structure. (A–D) N400 *pgI*<sub>ST-640</sub> has the *pgIB* allele responsible for synthesizing diNAcBac glycans. The strains KS351, KS352, and KS353 all produced two major signals that represent PiiE carrying the diNAcBac-AcHex disaccharide with one (17,734 Da) or two (17,857 Da) PE modifications. For KS354, the two major signals represent PiiE with diNAcBac monosaccharide with one (17,530 Da) or two (17,653 Da) PE modifications. (E–H) N400 *pgI*<sub>FAM18</sub> has the *pgIB2* allele accountable for synthesizing GATDH glycans. The strains KS360, KS361, and KS362, all produced signals that represent PiiE carrying GATDH-AcHex disaccharides with one (17,780 Da) or two (17,903 Da) PE modifications and also GATDH-Hex disaccharides with one (17,738 Da) or two (17,861 Da) PE modifications. For KS363, the two major signals represent PiiE with GATDH monosaccharides with one (17,576 Da) or two (17,699 Da) PE modifications. Also, KS361 produced two major signals that represent PiiE carrying GATDH monosaccharide with one or two PE modifications. Monosaccharides are indicated with molecular weights (in Da) boxed. All acetylated disaccharides are underlined. Table S2 shows all the ion species, *m/z* values, and corresponding molecular weights.

strate for PglH. As shown in Fig. 3, PglH is specific for transfer of glucose, showing that UDP-Glc is the preferred substrate of this enzyme and that UndPP-diNAcBac-Glc is the product of the reaction. To further confirm the identity of the radiolabeled product observed in the assay, the PglH product UndPP-diNAcBac-Glc was generated and treated under acidic conditions to hydrolyze the glycosyl diphosphate, and the resultant disaccharide was labeled with 2-aminobenzamide (2-AB). The fluorescently labeled sugar was purified by using normal-phase HPLC and the identity of the disaccharide peak was confirmed by MALDI MS, providing definitive evidence that PglH produces a disaccharide product comprising diNAcBac-Glc (Fig. S3).

PglB2 has not yet been biochemically characterized; therefore, the UndPP-GATDH substrate cannot be synthesized for the parallel assay with PglH. Instead, we examined the glycan monosaccharide


composition by using purified pilin derived from different backgrounds by GC after methanolysis and trimethylsilyl derivatization. This confirmed that the hexose transferred by PglH is glucose in the context of both diNAcBac and GATDH substrates (Fig. S4). We also examined the effects of a *galE* null mutation on glycoform expression. GalE catalyzes the interconversion between UDP-glucose and UDP-galactose, and neisserial *galE* mutants express galactose-deficient LPS (15) and galactose-deficient PiiE glycan (16). We confirmed the role of GalE in PglA-mediated disaccharide biosynthesis, as the null mutation creates a phenocopy of the *pgIA* mutant as seen by generation of the diNAcBac and GATDH-based glycoforms in MS analysis (strains KS354/KS357, KS363/KS366, and KS372/KS375; Table 1). In strains expressing *pgIB* alleles (synthesizing diNAcBac monosaccharide), these effects were detected by reactivity with the *npg1* mAb (Fig. S5A) in addition to MS analysis (Table 1). In contrast, the *galE* null mutation had no effect on disaccharide glycoform biosynthesis mediated by PglH as evidenced by MS analysis (strains KS356, KS365, and KS374; Table 1).

### Immunochemical Analysis of Glycans Synthesized in the Presence of PglH.

To examine the immunogenicity and antigenicity of the glycans synthesized by PglH, PiiE (in the form of purified pili) bearing the diNAcBac- and GATDH-based disaccharides were used to immunize rabbits, and the responses were monitored by immunoblotting with the *N. gonorrhoeae* strains and recombinants. As previously detailed, reactivity specific to other glycoproteins was used as a readout (6). The antibody response engendered by immunization with PiiE modified with the diNAcBac-AcGlc (from strain KS370, *pgI*<sub>Z2491</sub> *pgIA*) was specific to both diNAcBac- and GATDH-based PglH-derived glycans, whereas that following immunization with PiiE modified with the PglH-derived GATDH-AcGlc (from strain KS361, *pgI*<sub>FAM18</sub> *pgIA*) was more restricted, as it reacted with only the GATDH-AcGlc-expressing strains (Table 1 and Fig. S5 B and C). Taken together, these results show that protein-linked PglH-derived disaccharides are immunogenic and antigenic, and that both diNAcBac- and GATDH-based PglH-derived glycans act as glycosyl donors in general, broad-spectrum protein glycosylation. Moreover, these findings demonstrate that strains bearing active alleles of both *pgIA* and *pgIH* simultaneously express mixtures of glycoproteins with two distinct glycoforms (Table 1 and Figs. S2B and S5).

### Elaboration of UndPP-Disaccharides Generated in the Presence of PglH.

We next sought to examine whether PglE can further elaborate the PglH-generated disaccharide. MS analyses of PiiE purified from strains carrying *pgI*<sub>ST-640</sub>, *pgI*<sub>Z2491</sub>, or *pgI*<sub>FAM18</sub> in an otherwise N400 *pgIA* *pgIE*<sub>on</sub> background showed the presence of only the PglH-generated disaccharide (results for KS359, KS377, and KS368 are summarized in Table 1). PglE is therefore unable to modify the PglH-generated disaccharide. The galactose residues in the previously characterized di- and trisaccharide glycoforms (with the exception of the GATDH-based trisaccharide)



**Fig. 3.** PglH is a glucosyltransferase synthesizing disaccharide glycans. In vitro radioactivity-based assay using recombinantly expressed PglH from *N. meningitidis* strain Z2491 shows that it specifically transfers UDP-Glc (solid line) to Und-PP-diNAcBac. In comparison, PglH shows no transferase activity in the presence of UDP-Gal (round dot), UDP-GlcNAc (square dot), UDP-GalNAc (dash), and GDP-Man (dash/dot). Assays were performed in triplicate, and error bars indicate SD.

**Table 1. Pgl genotypes and phenotypes of strains**

Strain	Relevant genotype	Glycoform*	mAb <sup>†</sup>	pAb <sup>‡</sup>
<i>N. gonorrhoeae</i> N400 strains				
KS100	<i>recA6</i> (22)	diNAcBac-AcHex	npg2	—
KS141	<i>pgIA</i> (8)	diNAcBac	npg1	—
KS442	<i>galE</i>	nd	npg1	—
KS351	<i>pgI<sub>ST-640</sub></i>	diNAcBac-AcHex	npg2	pDAb2
KS352	<i>pgI<sub>ST-640</sub> pgIA</i>	diNAcBac-AcHex	—	pDAb2
KS353	<i>pgI<sub>ST-640</sub> pgIH</i>	diNAcBac-AcHex	npg2	—
KS354	<i>pgI<sub>ST-640</sub> pgIA pgIH</i>	diNAcBac	npg1	—
KS355	<i>pgI<sub>ST-640</sub> galE</i>	nd	—	pDAb2
KS356	<i>pgI<sub>ST-640</sub> pgIA galE</i>	diNAcBac-AcHex	—	pDAb2
KS357	<i>pgI<sub>ST-640</sub> pgIH galE</i>	diNAcBac	npg1	—
KS358	<i>pgI<sub>ST-640</sub> pgI<sub>E<sub>on</sub></sub></i>	diNAcBac-AcHexHex	npg3	pDAb2
KS359	<i>pgI<sub>ST-640</sub> pgI<sub>E<sub>on</sub></sub> pgIA</i>	diNAcBac-AcHex	—	pDAb2
KS419	<i>pgI<sub>ST-640</sub> pgIA pgII</i>	diNAcBac-Hex	—	pDAb2
KS416	<i>pgI<sub>ST-640</sub> pgIH pgII</i>	diNAcBac-Hex	npg2	—
KS387	<i>pgI<sub>ST-640</sub> pilE</i>	KS351	npg2	pDAb2
KS388	<i>pgI<sub>ST-640</sub> pgIA pilE</i>	KS352	—	pDAb2
KS389	<i>pgI<sub>ST-640</sub> pgIH pilE</i>	KS353	npg2	—
KS390	<i>pgI<sub>ST-640</sub> pgIA pgIH pilE</i>	KS354	npg1	—
KS360	<i>pgI<sub>FAM18</sub></i>	GATDH-AcHex	—	—
KS361	<i>pgI<sub>FAM18</sub> pgIA</i>	GATDH-AcHex	—	pDAb2
		GATDH	pGAb2	pGAb2
KS362	<i>pgI<sub>FAM18</sub> pgIH</i>	GATDH-AcHex	—	—
KS363	<i>pgI<sub>FAM18</sub> pgIA pgIH</i>	GATDH	—	—
KS364	<i>pgI<sub>FAM18</sub> galE</i>	nd	—	—
KS365	<i>pgI<sub>FAM18</sub> pgIA galE</i>	GATDH-AcHex	—	pDAb2
		GATDH	pGAb2	pGAb2
KS366	<i>pgI<sub>FAM18</sub> pgIH galE</i>	GATDH	—	—
KS367	<i>pgI<sub>FAM18</sub> pgI<sub>E<sub>on</sub></sub></i>	GATDH-AcHexHex	npg3	—
KS368	<i>pgI<sub>FAM18</sub> pgI<sub>E<sub>on</sub></sub> pgIA</i>	GATDH-AcHex	—	pDAb2
			pGAb2	pGAb2
KS420	<i>pgI<sub>FAM18</sub> pgIA pgII</i>	GATDH-Hex	—	pDAb2
			pGAb2	pGAb2
KS417	<i>pgI<sub>FAM18</sub> pgIH pgII</i>	GATDH-Hex	—	—
KS393	<i>pgI<sub>FAM18</sub> pilE</i>	KS360	—	—
KS394	<i>pgI<sub>FAM18</sub> pgIA pilE</i>	KS361	—	pDAb2
			pGAb2	pGAb2
KS395	<i>pgI<sub>FAM18</sub> pgIH pilE</i>	KS362	—	—
KS396	<i>pgI<sub>FAM18</sub> pgIA pgIH pilE</i>	KS363	—	—
KS369	<i>pgI<sub>Z2491</sub></i>	diNAcBac-AcHex	npg2	pDAb2
KS370	<i>pgI<sub>Z2491</sub> pgIA</i>	diNAcBac-AcHex	—	pDAb2
KS371	<i>pgI<sub>Z2491</sub> pgIH</i>	diNAcBac-AcHex	npg2	—
KS372	<i>pgI<sub>Z2491</sub> pgIA pgIH</i>	diNAcBac	npg1	—
KS373	<i>pgI<sub>Z2491</sub> galE</i>	nd	—	pDAb2
KS374	<i>pgI<sub>Z2491</sub> pgIA galE</i>	diNAcBac-AcHex	—	pDAb2
KS375	<i>pgI<sub>Z2491</sub> pgIH galE</i>	diNAcBac	npg1	—
KS376	<i>pgI<sub>Z2491</sub> pgI<sub>E<sub>on</sub></sub></i>	diNAcBac-AcHexHex	npg3	pDAb2
KS377	<i>pgI<sub>Z2491</sub> pgI<sub>E<sub>on</sub></sub> pgIA</i>	diNAcBac-AcHex	—	pDAb2
KS421	<i>pgI<sub>Z2491</sub> pgIA pgII</i>	diNAcBac-Hex	—	pDAb2
KS418	<i>pgI<sub>Z2491</sub> pgIH pgII</i>	diNAcBac-Hex	npg2	—
KS399	<i>pgI<sub>Z2491</sub> pilE</i>	KS369	npg2	pDAb2
KS400	<i>pgI<sub>Z2491</sub> pgIA pilE</i>	KS370	—	pDAb2
KS401	<i>pgI<sub>Z2491</sub> pgIH pilE</i>	KS371	npg2	—
KS402	<i>pgI<sub>Z2491</sub> pgIA pgIH pilE</i>	KS372	npg1	—
KS378	<i>pgI<sub>FA1090</sub></i>	diNAcBac-AcHex	npg2	—
KS379	<i>pgI<sub>FA1090</sub> pgIA</i>	diNAcBac	npg1	—
KS380	<i>pgI<sub>FA1090</sub> pgIH</i>	diNAcBac-AcHex	npg2	—
KS381	<i>pgI<sub>FA1090</sub> pgIA pgIH</i>	diNAcBac	npg1	—
KS382	<i>pgI<sub>FA1090</sub> galE</i>	nd	npg1	—
KS383	<i>pgI<sub>FA1090</sub> pgIA galE</i>	nd	npg1	—
KS384	<i>pgI<sub>FA1090</sub> pgIH galE</i>	nd	npg1	—
KS385	<i>pgI<sub>FA1090</sub> pgI<sub>E<sub>on</sub></sub></i>	diNAcBac-AcHexHex	npg3	—
KS386	<i>pgI<sub>FA1090</sub> pgI<sub>E<sub>on</sub></sub> pgIA</i>	nd	npg1	—

**Table 1. Cont.**

Strain	Relevant genotype	Glycoform*	mAb <sup>†</sup>	pAb <sup>‡</sup>
KS405	<i>pgI<sub>FA1090</sub> pilE</i>	KS378	npg2	—
KS406	<i>pgI<sub>FA1090</sub> pgIA pilE</i>	KS379	npg1	—
KS407	<i>pgI<sub>FA1090</sub> pgIH pilE</i>	KS380	npg2	—
KS408	<i>pgI<sub>FA1090</sub> pgIA pgIH pilE</i>	KS381	npg1	—
<i>N. gonorrhoeae</i> 4/3/1 ( <i>pilE<sub>ind</sub></i> ) strains				
KS101	<i>pilE<sub>ind</sub></i> (23)	nd	npg2	—
KS105	<i>pgIC</i> (5)	nd	—	—
KS122	<i>pgIA</i> (5)	nd	npg1	—
KS127	<i>pgI<sub>on</sub></i> (5)	nd	npg3	—
KS310	<i>pgIB<sub>28013</sub> pgI<sub>E<sub>on</sub></sub></i> (6)	nd	npg3	—
KS311	<i>pgIB<sub>28013</sub></i> (6)	nd	—	—
KS312	<i>pgIB<sub>28013</sub> pgIA</i> (6)	nd	—	—
4/3/1 strains, ectopic <i>lctP::pgIH</i> expression				
KS443	<i>pgIH<sub>ST-640</sub></i>	nd	npg2	pDAb2
KS444	<i>pgIH<sub>ST-640</sub> pgIA</i>	nd	—	pDAb2
KS454	<i>pgIH<sub>ST-640</sub> R373H pgIA</i>	nd	—	pDAb2
KS445	<i>pgIH<sub>Z2491</sub></i>	nd	npg2	pDAb2
KS446	<i>pgIH<sub>Z2491</sub> pgIA</i>	nd	—	pDAb2
KS456	<i>pgIH<sub>Z2491</sub> R371H pgIA</i>	nd	—	pDAb2
KS447	<i>pgIH<sub>FAM18</sub></i>	nd	npg2	—
KS448	<i>pgIH<sub>FAM18</sub> pgIA</i>	nd	npg1	pDAb2
KS458	<i>pgIH<sub>FAM18</sub> R373H pgIA</i>	nd	npg1	—
KS449	<i>pgIH<sub>FA1090</sub></i>	nd	npg2	—
KS450	<i>pgIH<sub>FA1090</sub> pgIA</i>	nd	npg1	—
KS451	<i>pgIH<sub>FA1090</sub> H371R</i>	nd	npg2	—
KS452	<i>pgIH<sub>FA1090</sub> H371R pgIA</i>	nd	npg1	pDAb2
<i>N. gonorrhoeae</i> FA1090 strains				
KS300	<i>recA6</i> (22)	diNAcBac, diNAcBac-AcHexHex	npg1 npg3	—
KS422	<i>pgIH</i>	diNAcBac, diNAcBac-AcHexHex	npg1 npg3	—
KS423	<i>pgIA pgIH</i>	diNAcBac	npg1	—
KS459	<i>pgIH<sub>H371R</sub></i>	nd	npg1 npg3	pDAb2
KS460	<i>pgIA pgIH<sub>H371R</sub></i>	nd	npg1	pDAb2


\* Glycoform (qualitative MS) or parental strain in which MS was performed. Hex, hexose; Ac, acetyl-group; nd, not determined.

<sup>†</sup>mAb reactivity, npg1 recognizes the monosaccharide diNAcBac; npg2 recognizes the disaccharide diNAcBac-Hex where galactose is added by PglA (i.e., diNAcBac-Gal); npg3 recognizes the trisaccharides diNAcBac-GalGal and GATDH-GalGal; —, no reactivity.

<sup>‡</sup>pAb reactivity, pDAb2 and pGAb2 recognize the disaccharides diNAcBac-Hex and GATDH-Hex, respectively, where glucose is added by PglH (i.e., diNAcBac-Glc and GATDH-Glc, respectively); —, no reactivity.

undergo *O*-acetylation by PglI (6, 8, 17). To explore whether PglI is responsible for acetylation of glucose in the PglH disaccharides, a *pgII* null mutation was introduced into the recombinant backgrounds. These strains synthesized nonacetylated disaccharides as demonstrated by MS analysis of purified PilE (results for KS419, KS416, KS420, KS417, KS421, and KS418 are summarized in Table 1).

**Polymorphisms in PglH Are Associated with Diminished Glycosyltransferase Activity.** To confirm that the effects seen in strains carrying different *pgl* loci were attributable to *pgIH* and not indirect effects associated with strain construction, recombinants were created in which *pgIH* alone was expressed from an ectopic site in otherwise unaltered backgrounds. By using immunoblot-based glycan serotyping, we confirmed that *pgIH* was both necessary and



**Fig. 4.** Identification of *pglH* polymorphisms associated with diminished glycosyltransferase activity. Expression of the diNAcBac-Glc disaccharide was monitored by reactivity of endogenous glycoproteins following immunoblotting with pDAb2 polyclonal antibody. (A) Variant alleles of *pglH* were expressed ectopically in the strain N400 derivative 4/3/1. In the strain expressing the *pglH*<sub>FAM18</sub> allele, glycoform-specific immunoreactivity was detected only in the *pglA*-null background, and in the strain expressing the *pglH*<sub>FA1090</sub> allele, no immunoreactivity was seen in either background. Conversion of H371R in the *pglH*<sub>FA1090</sub> allele partially restored activity but only in the *pglA* null background. Introduction of his in place of arg 371/373 in the other alleles had varying effects. Minus signs denote absence of the *pglH* gene or *pglA*::*kan*. Plus signs denote ectopically expressed *pglH* or intact *pglA*. Strains used are KS101, KS122, KS443, KS444, KS445, KS446, KS447, KS448, KS449, KS450, KS451, KS452, KS454, KS456, and KS458. (B) Mutation H371R in the endogenous *pglH* locus of strain FA1090 restores diNAcBac-Glc expression, and activity was seen in the presence of an intact *pglA* allele. Minus signs denote *pglA*::*kan* or *pglH*::*ermC/rpsL*; plus signs denote intact *pglA* or *pglH*. Strains used are KS300, KS422, KS459, KS423, and KS460. Arrow denotes the position of the major glycoprotein Pile.

sufficient for expression of the alternative disaccharide by using both UndPP-linked diNAcBac and GATDH as precursors (Fig. 4A). In addition, we found that the atypical glycosylation phenotypes observed for the FA1090- and FAM18-based recombinants could be directly attributed to their *pglH* genotypes.

To determine the nature of the defect manifest in the *pglH*<sub>FA1090</sub> ORF, a comparative alignment of PglH from several strains was examined (Fig. S6). This revealed one residue unique to PglH<sub>FA1090</sub> (and an identical allele in the gonococcal strain F62) at position 371 as a histidine versus a conserved arginine. A *pglH*<sub>FA1090</sub> allele in which the histidine codon at residue 371 was substituted with the arginine codon (H371R) restored PglH protein glycosylation activity as assessed by glycan serotyping. However, the reactivity was observed only in a *pglA* background, and the level of glycosylation was lower than that seen in strains expressing the other *pglH* alleles (Fig. 4A). Conversely, introducing the histidine 371 substitution into the *pglH*<sub>FAM18</sub> allele abolished the disaccharide glycosylation activity seen in the *pglA* background. However, making the equivalent mutations in the *pglH*<sub>Z2491</sub> and *pglH*<sub>ST-640</sub> alleles did not diminish glycosylation.

To corroborate the finding that polymorphisms at residue 371 influence PglH activity, the H371R mutation was introduced into the endogenous *pglH* gene of strain FA1090. As shown in Fig. 4B, the single amino acid substitution was sufficient to restore PglH activity in the WT FA1090 strain. Moreover, this effect was seen even in the presence of PglA, in contrast to observations in the N400 background. The disparate effect of the arginine substitution in the two backgrounds is not attributable to differences in PglH expression. Rather, it stems from polymorphisms in *pglA*, as *pglA*<sub>FA1090</sub> has previously been shown to be associated with reduced activity relative to that of the allele in strain N400 (6). Together, these findings document epistatic interactions involving *pglH* at the intragenic and intergenic levels.


## Discussion

Although the presence of a widely distributed deletion within the *pgl* core locus of *Neisseria* species was established more than 10 years ago, the biological consequences of this gross polymorphism

remained elusive. Here, we establish that PglH, corresponding to one of two ORFs encompassed within the deletion, encodes a glycosyltransferase that acts to synthesize disaccharides by using UndPP-linked forms of diNAcBac and GATDH as substrates. Together with the protein-associated glycans previously defined, these two disaccharides in their unmodified and *O*-acetylated forms expand the pan-neisserial glycome to include 13 distinct glycoforms. These findings also definitively link a pervasive genome rearrangement disseminated at the genus level to a reduction in protein glycoform repertoire.

We also observed surprisingly high levels of polymorphism within *pglH*, and, in two cases, we were able to demonstrate corresponding functional alterations indicative of altered selection. The first case is that exemplified by the allele found in gonococcal strains FA1090 and F62. Here, the gene product is devoid of detectable glycosyltransferase activity as measured *in vivo*. The basis for this defect was mapped to residue 371, as restoration of a consensus arginine residue (in place of histidine) resurrected activity both in the ectopic locus in N400 as well as in the native locus of FA1090. The allele carried in gonococcal strain SK-92-679 may also encode a defective transferase, as it encodes a proline rather than the consensus arginine at this site (Fig. S6). The second case is that associated with the *pglH*<sub>FAM18</sub> allele, which encodes a functional product but whose activity is diminished as seen by an admixture of both monosaccharide and disaccharide forms in its presence. Furthermore, *pglH*<sub>FAM18</sub> is unable to exert its activity in the presence of PglA.

The disseminated distribution of the deleted ORF2/*pglH* variant strongly suggests that this polymorphism is linked to altered fitness related to protein glycosylation. However, it is difficult to exclude that this situation reflects selection at a tightly linked locus and that the prevalence of the deletion is caused by unrelated effects. The existence of *pglH* missense alleles associated with non-detectable and reduced transferase activities argues against this scenario, and thus strengthens the idea that the glucose-containing disaccharide itself currently represents a trait in the active process of regression. If this is the case, to what can we ascribe this regressive nature? We propose that genetic interactions between *pglA* and *pglH* are likely to play a major role. As both glycosyltransferases result in the synthesis of disaccharides by



**Fig. 5.** PglA and PglH compete for substrates generated by PglB/PglB2 in a branched pathway for protein glycan biosynthesis. (A) PglH is involved in the broad-spectrum *O*-linked glycosylation systems in *Neisseria* by adding glucose onto diNAcBac or GATDH UndPP monosaccharide. (B) The figure displays the chemical reactions of the phospho-glycosyltransferases, PglB/PglB2, and the glycosyltransferases, PglA and PglH. Boxed are the substrates (R) for the two glycosyltransferases, PglB and PglB2, and side groups (R') on the glycans. Und, undecaprenol; UDP, uridine diphosphate.

using shared monosaccharide substrates (Fig. 5 and Fig. S7), redundancy may have allowed the passive accumulation of *pglH* mutations. Alternatively, incompatibility or conflict mediated by competition between the two pathways may have led to active selection. Although the activities of PglA and PglH are not mutually exclusive of one another (in the laboratory), the PglH activity precludes synthesis of the trisaccharide glycoform mediated by PglE. It is also conceivable that genetic antagonism imposed by the bifurcated pathway might be resolved by regressive alleles of *pglA* as suggested by the low activity associated with the FA1090 gene (6). An interesting facet of the “active-selection hypothesis” is that both *pglA* and *pglH* are capable of high-frequency, on/off expression as a result of hotspots for frame-shifting events in the ORFs. Theoretically, such a mechanism could significantly ameliorate the potential for pathway incompatibility. However, some *pglA* and *pglH* alleles lack the sequences driving phase variation, and strains carrying them will invariably express galactose- or glucose-containing oligosaccharides, respectively. Further studies of connections between the phase variability status and genotypes are ongoing.

As the roles of *O*-linked protein glycosylation in neisserial species remain poorly understood, attempts to define the functional consequences of an altered glycan repertoire are somewhat limited. Glycan diversification may be driven by selection at the level of the adaptive and innate immune systems. Hamadeh and colleagues reported that human serum and IgA1 polyclonal antibodies directed toward terminal galactose residues bound to meningococcal pili and blocked complement-mediated lysis (18). Although the mechanistic details behind those observations remain unknown, *pglH* expression would likely preclude or diminish recognition of glycoproteins by anti-Gal antibodies. Banerjee and colleagues reported that phase variable alleles of *pglA* were overrepresented in isolates associated with disseminated forms of disease (19). This finding was refuted by a subsequent study that failed to find an absolute correlation between disease manifestation and *pglA* phase-variable status (20). Our findings on *pglH* and its interactions with *pglA* indicate that broader studies are needed to assess the potential influence of *O*-linked protein glycosylation on the propensity of strains to promote disseminated gonococcal disease.

In conclusion, the prevalent loss of *pglH* mediated by deletion, together with the presence of alleles encoding defective products,

corresponds to a significant reduction in glycan diversity. The pervasive deletion of *pglH* represents the second major alteration of *pgl* gene content impacting at the genus level, following that documented for the introgression of the *pglB2* allele (9). Thus, the work clearly demonstrates that gene loss as well as gene acquisition can drive protein glycan macroevolution. Finally, we found strong evidence that intrinsic genetic interactions may contribute to the evolutionary trajectory of protein glycosylation systems.

## Materials and Methods

**Bacterial Strains and Culture Conditions.** The bacterial strains used in this study are described in Table 1 and in *SI Materials and Methods*.

**SDS/PAGE and Immunoblotting.** Procedures for SDS/PAGE and immunoblotting have been previously described (21). Immunoreactive proteins were detected by immunoblotting by using the glycan-specific monoclonal antibodies npg1, npg2, and npg3 (6), rabbit polyclonal antibodies pDAb2 and pGAb2 (*SI Materials and Methods*), and alkaline phosphatase-coupled goat anti-rabbit secondary antibodies (Sigma).

**Sample Preparation and ESI MS Analysis of Intact Pile.** Type IV pili were isolated and treated with a methanol/chloroform wash/precipitation procedure as described (8). Data were acquired on a quadrupole time-of-flight mass spectrometer (Q-ToF micro; Waters) equipped with the standard Z-spray ESI source as previously described (6, 8).

**In Vitro Radioactivity-Based Assay.** The glycosyltransferase PglH was heterologously overexpressed in *Escherichia coli* and purified as a MBP fusion protein as described in *SI Materials and Methods*. The ability of PglH to transfer UDP-Glc, UDP-Gal, UDP-GlcNAc, UDP-GalNAc, and GDP-Man was analyzed by using a radioactivity-based assay, and the identity of the PglH product was verified via characterization of the 2-AB-labeled glycan. Further details are described in *SI Materials and Methods*.

**ACKNOWLEDGMENTS.** The authors thank Jos van Putten for providing the *N. gonorrhoeae* *galE* mutant and Warren Wakarchuk for helpful discussions on the structure–function relationships of PglH. This research was supported in part by Research Council of Norway Grants 166931, 183613, and 183814; by funds from the Department of Molecular Biosciences and Center for Molecular Biology and Neurosciences of the University of Oslo; and by National Institutes of Health Grant GM039334.

- Nothhaft H, Szymanski CM (2010) Protein glycosylation in bacteria: Sweeter than ever. *Nat Rev Microbiol* 8:765–778.
- Champion OL, et al. (2005) Comparative phylogenomics of the food-borne pathogen *Campylobacter jejuni* reveals genetic markers predictive of infection source. *Proc Natl Acad Sci USA* 102:16043–16048.
- Carter AT, et al. (2009) Independent evolution of neurotoxin and flagellar genetic loci in proteolytic *Clostridium botulinum*. *BMC Genomics* 10:115.
- Twine SM, et al. (2009) Motility and flagellar glycosylation in *Clostridium difficile*. *J Bacteriol* 191:7050–7062.
- Vik A, et al. (2009) Broad spectrum *O*-linked protein glycosylation in the human pathogen *Neisseria gonorrhoeae*. *Proc Natl Acad Sci USA* 106:4447–4452.
- Borud B, et al. (2010) Genetic, structural, and antigenic analyses of glycan diversity in the *O*-linked protein glycosylation systems of human *Neisseria* species. *J Bacteriol* 192:2816–2829.
- Power PM, et al. (2003) Genetic characterization of pilin glycosylation and phase variation in *Neisseria meningitidis*. *Mol Microbiol* 49:833–847.
- Aas FE, Vik A, Vedde J, Koomey M, Egge-Jacobsen W (2007) *Neisseria gonorrhoeae* *O*-linked pilin glycosylation: functional analyses define both the biosynthetic pathway and glycan structure. *Mol Microbiol* 65:607–624.
- Chamot-Rooke J, et al. (2007) Alternative *Neisseria* spp. type IV pilin glycosylation with a glyceramido acetamido trideoxyhexose residue. *Proc Natl Acad Sci USA* 104:14783–14788.
- Kahler CM, et al. (2001) Polymorphisms in pilin glycosylation locus of *Neisseria meningitidis* expressing class II pili. *Infect Immun* 69:3597–3604.
- Hartley MD, et al. (2011) Biochemical characterization of the *O*-linked glycosylation pathway in *Neisseria gonorrhoeae* responsible for biosynthesis of protein glycans containing *N,N'*-diacetylglucosamine. *Biochemistry*, May 12 (Epub ahead of print).
- Bentley SD, et al. (2006) Genetic analysis of the capsular biosynthetic locus from all 90 pneumococcal serotypes. *PLoS Genet* 2:e31.
- Wang L, Wang Q, Reeves PR (2010) The variation of *O* antigens in gram-negative bacteria. *Subcell Biochem* 53:123–152.
- Hegge FT, et al. (2004) Unique modifications with phosphocholine and phosphoethanolamine define alternate antigenic forms of *Neisseria gonorrhoeae* type IV pili. *Proc Natl Acad Sci USA* 101:10798–10803.
- Robertson BD, Frosch M, van Putten JP (1993) The role of *galE* in the biosynthesis and function of gonococcal lipopolysaccharide. *Mol Microbiol* 8:891–901.
- Stimson E, et al. (1995) Meningococcal pilin: A glycoprotein substituted with digalactosyl 2,4-diacetamido-2,4,6-trideoxyhexose. *Mol Microbiol* 17:1201–1214.
- Warren MJ, Roddam LF, Power PM, Terry TD, Jennings MP (2004) Analysis of the role of *pgll* in pilin glycosylation of *Neisseria meningitidis*. *FEMS Immunol Med Microbiol* 41:43–50.
- Hamadeh RM, Estabrook MM, Zhou P, Jarvis GA, Griffiss JM (1995) Anti-Gal binds to pili of *Neisseria meningitidis*: the immunoglobulin A isotype blocks complement-mediated killing. *Infect Immun* 63:4900–4906.
- Banerjee A, et al. (2002) Implications of phase variation of a gene (*pgtA*) encoding a pilin galactosyl transferase in gonococcal pathogenesis. *J Exp Med* 196:147–162.
- Power PM, et al. (2007) The phase-variable allele of the pilus glycosylation gene *pglA* is not strongly associated with strains of *Neisseria gonorrhoeae* isolated from patients with disseminated gonococcal infection. *Infect Immun* 75:3202–3204.
- Freitag NE, Seifert HS, Koomey M (1995) Characterization of the *pilF-pilD* pilus-assembly locus of *Neisseria gonorrhoeae*. *Mol Microbiol* 16:575–586.
- Tonjum T, Freitag NE, Namork E, Koomey M (1995) Identification and characterization of *pilG*, a highly conserved pilus-assembly gene in pathogenic *Neisseria*. *Mol Microbiol* 16:451–464.
- Wolfgang M, van Putten JP, Hayes SF, Dorward D, Koomey M (2000) Components and dynamics of fiber formation define a ubiquitous biogenesis pathway for bacterial pili. *Embo J* 19:6408–6418.